We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.

Accept essential cookies
Accept all cookies
U.S. Pharmaceutical Preparation Market. Analysis And Forecast to 2030
Report Update: Jun 1, 2025

U.S. Pharmaceutical Preparation Market. Analysis And Forecast to 2030

Single report
Sent by email within 24h (Mon-Fri)
What's the difference?
Subscription
Online access and download
from $350/month

Get instant access to more than 2 million reports, dashboards, and datasets on the IndexBox Platform.

View Pricing
January 10, 2025 at 12:53 PM GMT+0

Walgreens Exceeds Earnings Expectations Despite Fiscal Challenges

Walgreens has reported first-quarter fiscal results that surpassed Wall Street's expectations, with earnings signaling positive growth amidst multiple strategic moves including store closures and cost-cutting measures. According to CNBC, the company's efforts appear to be part of a larger plan to regain stability after a tumultuous year.

In the fiscal first quarter, Walgreens achieved sales of $39.46 billion, reflecting a 7.5% increase from the previous year. This growth was seen across all three of its business segments. A detailed report from IndexBox highlights that pharmacy sales for the quarter surged by 10.4%, influenced by rising brand medication prices and a total of 316.3 million prescriptions filled, including vaccines — a 1.5% increase from the prior year.

Conversely, the company recorded a net loss of $265 million, translating to a loss of 31 cents per share. This compares to a net loss of $67 million in the same period last year. Walgreens attributes the deepened losses chiefly to operational expenses associated with its strategy to close underperforming stores, aiming to shutter approximately 1,200 locations over the next three years.

The U.S. retail pharmacy division generated $30.87 billion in sales, exceeding analyst predictions of $29.21 billion. This division is integral to Walgreens' operations, encompassing the sales of both prescription and non-prescription medications, alongside various health and wellness products. Meanwhile, the company's U.S. healthcare unit reflected significant growth by reporting $2.17 billion in sales, surpassing the forecasted $2.09 billion.

The international business segment also saw a noteworthy rise, with sales at $6.43 billion, marking a 10.2% advance from the prior year, outperforming the anticipated $5.85 billion in revenues. Boots, Walgreens' U.K.-based chain, also contributed positively with a 4.5% sales increase, demonstrating resilience in foreign markets.

Despite these positive metrics, analyzed data from IndexBox indicates that Walgreens continues to face challenges. Retail sales experienced a drop of 6.2%, coinciding with weaker demand in discretionary product categories, coupled with a less severe cough, cold, and flu season.

CEO Tim Wentworth, in the company release, emphasized Walgreens' commitment to its 2025 objectives, focusing on cost optimization, cash flow improvements, and continued development of sustainable, retail pharmacy-led operations. The company's ongoing discussions about a potential sale to private equity firm Sycamore Partners further underline the strategic shifts at the core of its transformation drive.

Source: IndexBox Market Intelligence Platform

This report provides an in-depth analysis of the pharmaceutical preparation market in the U.S.. Within it, you will discover the latest data on market trends and opportunities by country, consumption, production and price developments, as well as the global trade (imports and exports). The forecast exhibits the market prospects through 2030.

Product coverage:

  • NAICS 325412 - Pharmaceutical preparation manufacturing

Companies mentioned:

  • Pfizer Inc.
  • Merck & Co.
  • Abbott Laboratories
  • Abbvie Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Genentech
  • Baxter International
  • Allergan
  • Biogen, Glaxosmithkline
  • Celgene Corporation
  • Hospira
  • Alere
  • Perrigo Company
  • Mylan Inc.
  • Regeneron Pharmaceuticals
  • Novartis Corporation
  • Alexion Pharmaceuticals
  • Genzyme Corporation
  • Zoetis
  • Sanofi US Services
  • Olympus Partners
  • Valeant Pharmaceuticals International
  • Merck Sharp & Dohme Corp.
  • Glaxosmithkline Holdings (Americas)
  • Wyeth
  • Astrazeneca Pharmaceuticals
  • Actavis Inc.
  • Alcon Laboratories Holding Corporation
  • Roche Holdings

Country coverage:

  • United States

Data coverage:

  • Market volume and value
  • Per Capita consumption
  • Forecast of the market dynamics in the medium term
  • Trade (exports and imports) in the U.S.
  • Export and import prices
  • Market trends, drivers and restraints
  • Key market players and their profiles

Reasons to buy this report:

  • Take advantage of the latest data
  • Find deeper insights into current market developments
  • Discover vital success factors affecting the market

This report is designed for manufacturers, distributors, importers, and wholesalers, as well as for investors, consultants and advisors.

In this report, you can find information that helps you to make informed decisions on the following issues:

  1. How to diversify your business and benefit from new market opportunities
  2. How to load your idle production capacity
  3. How to boost your sales on overseas markets
  4. How to increase your profit margins
  5. How to make your supply chain more sustainable
  6. How to reduce your production and supply chain costs
  7. How to outsource production to other countries
  8. How to prepare your business for global expansion

While doing this research, we combine the accumulated expertise of our analysts and the capabilities of artificial intelligence. The AI-based platform, developed by our data scientists, constitutes the key working tool for business analysts, empowering them to discover deep insights and ideas from the marketing data.

  1. 1. INTRODUCTION

    Making Data-Driven Decisions to Grow Your Business

    1. REPORT DESCRIPTION
    2. RESEARCH METHODOLOGY AND THE AI PLATFORM
    3. DATA-DRIVEN DECISIONS FOR YOUR BUSINESS
    4. GLOSSARY AND SPECIFIC TERMS

  2. 2. EXECUTIVE SUMMARY

    A Quick Overview of Market Performance

    1. KEY FINDINGS
    2. MARKET TRENDSThis Chapter is Available Only for the Professional EditionPRO

  3. 3. MARKET OVERVIEW

    Understanding the Current State of The Market and its Prospects

    1. MARKET SIZE: HISTORICAL DATA (2012–2024) AND FORECAST (2025–2035)
    2. MARKET STRUCTURE: HISTORICAL DATA (2012–2024) AND FORECAST (2025–2035)
    3. TRADE BALANCE: HISTORICAL DATA (2012–2024) AND FORECAST (2025–2035)
    4. PER CAPITA CONSUMPTION: HISTORICAL DATA (2012–2024) AND FORECAST (2025–2035)
    5. MARKET FORECAST TO 2035

  4. 4. MOST PROMISING PRODUCTS FOR DIVERSIFICATION

    Finding New Products to Diversify Your Business

    1. TOP PRODUCTS TO DIVERSIFY YOUR BUSINESS
    2. BEST-SELLING PRODUCTS
    3. MOST CONSUMED PRODUCTS
    4. MOST TRADED PRODUCTS
    5. MOST PROFITABLE PRODUCTS FOR EXPORTS

  5. 5. MOST PROMISING SUPPLYING COUNTRIES

    Choosing the Best Countries to Establish Your Sustainable Supply Chain

    1. TOP COUNTRIES TO SOURCE YOUR PRODUCT
    2. TOP PRODUCING COUNTRIES
    3. TOP EXPORTING COUNTRIES
    4. LOW-COST EXPORTING COUNTRIES

  6. 6. MOST PROMISING OVERSEAS MARKETS

    Choosing the Best Countries to Boost Your Export

    1. TOP OVERSEAS MARKETS FOR EXPORTING YOUR PRODUCT
    2. TOP CONSUMING MARKETS
    3. UNSATURATED MARKETS
    4. TOP IMPORTING MARKETS
    5. MOST PROFITABLE MARKETS

  7. 7. PRODUCTION

    The Latest Trends and Insights into The Industry

    1. PRODUCTION VOLUME AND VALUE: HISTORICAL DATA (2012–2024) AND FORECAST (2025–2035)

  8. 8. IMPORTS

    The Largest Import Supplying Countries

    1. IMPORTS: HISTORICAL DATA (2012–2024) AND FORECAST (2025–2035)
    2. IMPORTS BY COUNTRY: HISTORICAL DATA (2012–2024)
    3. IMPORT PRICES BY COUNTRY: HISTORICAL DATA (2012–2024)

  9. 9. EXPORTS

    The Largest Destinations for Exports

    1. EXPORTS: HISTORICAL DATA (2012–2024) AND FORECAST (2025–2035)
    2. EXPORTS BY COUNTRY: HISTORICAL DATA (2012–2024)
    3. EXPORT PRICES BY COUNTRY: HISTORICAL DATA (2012–2024)

  10. 10. PROFILES OF MAJOR PRODUCERS

    The Largest Producers on The Market and Their Profiles

  11. LIST OF TABLES

    1. Key Findings In 2024
    2. Market Volume, In Physical Terms: Historical Data (2012–2024) and Forecast (2025–2035)
    3. Market Value: Historical Data (2012–2024) and Forecast (2025–2035)
    4. Per Capita Consumption: Historical Data (2012–2024) and Forecast (2025–2035)
    5. Imports, In Physical Terms, By Country, 2012–2024
    6. Imports, In Value Terms, By Country, 2012–2024
    7. Import Prices, By Country, 2012–2024
    8. Exports, In Physical Terms, By Country, 2012–2024
    9. Exports, In Value Terms, By Country, 2012–2024
    10. Export Prices, By Country, 2012–2024

  12. LIST OF FIGURES

    1. Market Volume, In Physical Terms: Historical Data (2012–2024) and Forecast (2025–2035)
    2. Market Value: Historical Data (2012–2024) and Forecast (2025–2035)
    3. Market Structure – Domestic Supply vs. Imports, in Physical Terms: Historical Data (2012–2024) and Forecast (2025–2035)
    4. Market Structure – Domestic Supply vs. Imports, in Value Terms: Historical Data (2012–2024) and Forecast (2025–2035)
    5. Trade Balance, In Physical Terms: Historical Data (2012–2024) and Forecast (2025–2035)
    6. Trade Balance, In Value Terms: Historical Data (2012–2024) and Forecast (2025–2035)
    7. Per Capita Consumption: Historical Data (2012–2024) and Forecast (2025–2035)
    8. Market Volume Forecast to 2035
    9. Market Value Forecast to 2035
    10. Market Size and Growth, By Product
    11. Average Per Capita Consumption, By Product
    12. Exports and Growth, By Product
    13. Export Prices and Growth, By Product
    14. Production Volume and Growth
    15. Exports and Growth
    16. Export Prices and Growth
    17. Market Size and Growth
    18. Per Capita Consumption
    19. Imports and Growth
    20. Import Prices
    21. Production, In Physical Terms: Historical Data (2012–2024) and Forecast (2025–2035)
    22. Production, In Value Terms: Historical Data (2012–2024) and Forecast (2025–2035)
    23. Imports, In Physical Terms: Historical Data (2012–2024) and Forecast (2025–2035)
    24. Imports, In Value Terms: Historical Data (2012–2024) and Forecast (2025–2035)
    25. Imports, In Physical Terms, By Country, 2024
    26. Imports, In Physical Terms, By Country, 2012–2024
    27. Imports, In Value Terms, By Country, 2012–2024
    28. Import Prices, By Country, 2012–2024
    29. Exports, In Physical Terms: Historical Data (2012–2024) and Forecast (2025–2035)
    30. Exports, In Value Terms: Historical Data (2012–2024) and Forecast (2025–2035)
    31. Exports, In Physical Terms, By Country, 2024
    32. Exports, In Physical Terms, By Country, 2012–2024
    33. Exports, In Value Terms, By Country, 2012–2024
    34. Export Prices, By Country, 2012–2024

Recommended posts

Free Data: Pharmaceutical Preparation - United States
Table
Pharmaceutical Preparation - United States - Table
Dashboard
Pharmaceutical Preparation - United States - Dashboard
Report
Pharmaceutical Preparation - United States - Report